ÂÜÀòÂÒÂ×

Dr. Danos has over 30 years of experience in gene therapy, as a scientist pioneering gene transfer technologies and as a leader in the biotech and pharmaceutical industry. He currently serves as the Chief Scientific Officer (CSO) of RegenxBio (Nasdaq: RGNX), a clinical-stage biotechnology company developing a proprietary adeno-associated virus (AAV) gene delivery platform for the treatment of retinal, neurodegenerative, and metabolic diseases.

Prior to RegenxBio, Olivier has undertaken a number of clinical research and executive leadership roles including Senior Vice President at Biogen and Kadmon Pharmaceuticals, Director of the Gene Therapy Consortium at UCL, CSO at Genethon, as well as Director of Research at the CNRS (Centre national de la recherche scientifique – The French National Centre for Scientific Research) and Principal Investigator at Institut Pasteur. Olivier completed his Ph.D. at the University of Paris Diderot.